SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-234005
Filing Date
2021-08-03
Accepted
2021-08-03 07:14:58
Documents
14
Period of Report
2021-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d191671d8k.htm   iXBRL 8-K 25256
2 EX-99.1 d191671dex991.htm EX-99.1 92786
6 GRAPHIC g191671g0803065818782.jpg GRAPHIC 5859
  Complete submission text file 0001193125-21-234005.txt   258740

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20210803.xsd EX-101.SCH 2905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20210803_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20210803_pre.xml EX-101.PRE 10961
7 EXTRACTED XBRL INSTANCE DOCUMENT d191671d8k_htm.xml XML 3246
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 211137957
SIC: 2834 Pharmaceutical Preparations